Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Rhea-AI Summary

Ocugen's Chief Scientific Officer, Dr. Arun Upadhyay, is set to participate in the 5th Annual Gene Therapy for Ophthalmic Disorders Summit in Boston from September 10-12, 2024. Dr. Upadhyay will moderate a workshop on regulatory pathways for ophthalmic gene therapies on September 10 and deliver a presentation on Ocugen's clinical program updates on September 12.

Ocugen (NASDAQ: OCGN) is a biotechnology company focused on gene and cell therapies, and vaccines. Dr. Upadhyay emphasized the potential of gene therapy in treating rare retinal diseases and widespread ophthalmic conditions. The conference provides an opportunity for Ocugen to showcase its modifier gene therapy platform and stay updated on industry advancements.

News Market Reaction

+1.72%

1 alert

+1.72% News Effect

On the day this news was published, OCGN gained 1.72%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research & Development, will be among the featured speakers at the 5^th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held September 10-12, 2024 in Boston, Mass.

“There is tremendous potential for gene therapy to treat both rare retinal diseases and ophthalmic diseases affecting millions,” said Dr. Upadhyay. “I look forward to sharing the development and clinical progress of Ocugen’s modifier gene therapy platform with my peers and learning about the latest advancements in the field from industry experts.”

Details regarding Dr. Upadhyay’s participation are as follows:

Workshop Moderator
Topic: Navigating Regulatory Pathways for Ophthalmic Gene Therapies
Date: Tuesday, September 10, 2024
Time: 1-4 p.m. ET

Presentation
Topic: Advancements in Gene Therapy for Opthalmic Disorders: Ocugen’s Clinical Program Updates
Date: Thursday, September 12, 2024
Time: 11:30 a.m.-noon

About Ocugen, Inc. 
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. 

Contact: 
Tiffany Hamilton 
Head of Communications 
Tiffany.Hamilton@ocugen.com

FAQ

When and where is Ocugen (OCGN) participating in the Gene Therapy for Ophthalmic Disorders Summit?

Ocugen (OCGN) is participating in the 5th Annual Gene Therapy for Ophthalmic Disorders Summit from September 10-12, 2024, in Boston, Massachusetts.

What role will Ocugen's (OCGN) Chief Scientific Officer play at the 2024 ophthalmic gene therapy conference?

Dr. Arun Upadhyay, Ocugen's (OCGN) Chief Scientific Officer, will moderate a workshop on regulatory pathways for ophthalmic gene therapies on September 10 and give a presentation on Ocugen's clinical program updates on September 12, 2024.

What is the focus of Ocugen's (OCGN) research as mentioned in the 2024 conference announcement?

Ocugen (OCGN) is focused on developing gene therapies for rare retinal diseases and ophthalmic conditions affecting millions, utilizing their modifier gene therapy platform.

What types of therapies and products is Ocugen (OCGN) working on according to the 2024 press release?

According to the press release, Ocugen (OCGN) is a biotechnology company working on discovering, developing, and commercializing novel gene and cell therapies, as well as vaccines.